Small Cap Pharma Stock To Consider Bonus Shares On August 02, Scrip Up 64.02% In 3 Months

Infinium Pharmachem Ltd. has announced in an exchange filing that the company is to consider & approve the Issue of Bonus Shares to the shareholders of the company on Aug 02, 2023. The Board informed the same in a Board meeting held on Wednesday, Jul 19, 2023.

Infinium Pharmachem Ltd. is a Small Cap SME that operates in the Pharma sector. It has a market cap of Rs 204.91 Crore.

August 02, Board Meeting

According to an exchange filing by the Board of Directors of Infinium Pharmachem Ltd., the meeting of the Board of Directors of the Company is scheduled to be held on Wednesday, AUGUST 2, 2023 at the Registered Office of the Company to consider, inter alia, the following items:

1. To consider and recommend the Statement of Profit & Loss for the Financial Year ended March 31, 2023 and the Balance Sheet as on that date and the Reports of the Directors and Auditors thereon.
2. To fix date, time and venue for conducting the AGM of the Company for the financial year ended on 31st March, 2023.
3. To consider and approve the Draft Notice of Annual General Meeting (AGM) for the financial year ended on 31st March, 2023.
4. To consider increase in Authorized share capital of the company.
5. To consider and approve lssue of Bonus Shares to the Shareholders of the Company.
6. Any other agenda with the permission of Chair

Stock Movement

The stock's current market price is Rs 294.50 apiece on NSE, up 1.398% from its previous close of Rs 290.50 apiece. The stock's 52-week high is Rs 296 apiece and its 52-week low is Rs 292.90 apiece. In the last 1 week, it gained 10.3%, while in 1 and 3 months, it gained 4.77% and 64.02%, respectively.

Disclaimer - The stock just highlights the Bonus Shares and is not a recommendation to buy, sell or hold. We have not done fundamental or technical analysis and have no opinion on the stock mentioned. Neither the author nor Greynium Information Technologies should be held liable for any losses. Please consult a professional advisor.